

## Potassium Phosphate

| <b>CAUTION: High Administration Risk Rating</b> |  |  |
|---|--|--|
| <b>Form &amp; Storage</b>                       | 20mL ampoule containing 1mmol potassium and 0.6mmol phosphate per mL (each ampoule contains 20mmol potassium, 12mmol phosphate)  | Concentrated potassium ampoules must be stored in the Controlled Drug press. |
| <b>Reconstitution</b>                           | Already in solution<br><b>Further dilution is essential before administration</b>  |  |
| <b>Compatibility &amp; Stability</b>            | Sodium Chloride 0.9%<br>Glucose 5%   |  |
| <b>Administration</b>                           | <p><b><u>IV Infusion ONLY</u></b></p> <p>20mL ampoule must be diluted with at least 500mL of compatible fluid, and <b>mixed well</b>.</p> <ul style="list-style-type: none"> <li>• Administer via central venous access device or large peripheral vein.</li> <li>• Concentration: Maximum concentration is 40mmol potassium in 1L.</li> <li>• Rate:               <ul style="list-style-type: none"> <li>○ Usual maximum infusion rate is 10mmol Potassium (6mmols Phosphate) per hour.</li> <li>○ Administer over at least 2 hours.</li> </ul> </li> </ul> |  |
| <b>Monitoring</b>                               | Monitor ECG, plasma potassium, phosphate and calcium concentrations closely when rate of intravenous potassium exceeds 20mmol per hour. REFER TO ITU FOR GUIDANCE.   |  |
| <b>Extravasation</b>                            | <ul style="list-style-type: none"> <li>• Venous irritation or phlebitis may occur at injection site where solutions contain more than 30mmol of potassium per litre.</li> <li>• Particular care should be taken to ensure that infusion is intravenous, since paravenous administration can lead to indurations and chalky deposits in the subcutaneous tissue.</li> </ul>   |  |
| <b>Additional Information</b>                   | Higher rates and concentrations may be used in ITU.  |  |

**Information provided relates to Potassium Phosphate manufactured by B Braun.**

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*